The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

Market Growth Overview

The transmucosal drug delivery devices market has seen significant growth recently, expanding from $46.16 billion in 2023 to an estimated $50.24 billion in 2024, reflecting a compound annual growth rate (CAGR) of 8.8%. This growth is driven by several key factors, including:

• Need for Rapid Relief: Quick relief from conditions like angina drives the demand for fast-acting drug delivery methods.
• Sublingual Effectiveness: Sublingual delivery allows for rapid absorption into the bloodstream, bypassing the gastrointestinal system.
• Non-Invasive Methods: The market is also expanding due to the development of non-invasive delivery systems, particularly for peptides and proteins.

Expected Market Expansion

Looking ahead, the market is projected to reach $71.69 billion by 2028, with a CAGR of 9.3%. Several factors contribute to this robust forecast:

• Smart Delivery Systems: Innovations in smart drug delivery are making treatment more personalized and efficient.
• Chronic Disease Prevalence: As chronic diseases become more widespread, the demand for efficient drug delivery systems increases.
• Aging Population: An aging global population with increased medication needs fuels market growth.

View More On The Transmucosal Drug Delivery Devices Market Report 2024 – https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report

Major Trends in the Forecast Period

Key trends expected to shape the market include:

• Therapeutic Applications Expansion: Broadened use of transmucosal devices across various medical fields.
• Customization for Personalized Medicine: Development of devices tailored to individual patient needs.
• Eco-Friendly Devices: Growing emphasis on environmentally sustainable drug delivery solutions.

Impact of Chronic Diseases on Market Growth

The rising prevalence of chronic diseases is a significant driver of the transmucosal drug delivery devices market. Chronic diseases, such as diabetes and cardiovascular conditions, require consistent medication management, making efficient and sustained drug delivery crucial.

• Rising Diabetes Cases: According to the International Diabetes Federation (IDF), approximately 537 million people globally have diabetes, a number expected to increase to 783 million by 2045.
• Effective Management: Transmucosal devices offer controlled delivery of medications, ensuring sustained therapeutic levels, improving patient adherence, and enhancing treatment outcomes.

Innovations in Transmucosal Drug Delivery

The market is witnessing numerous innovations aimed at improving drug delivery methods. Companies are developing proprietary transdermal patch delivery platforms designed to enhance drug absorption and patient convenience.

• Smart Platforms: For example, Starton Therapeutics Inc. launched STARSILON, a novel transdermal patch delivery platform, in January 2024. This platform allows for sustained delivery of challenging active pharmaceutical ingredients (APIs), improving therapeutic efficacy.

Strategic Acquisitions in the Market

To strengthen their positions, companies are engaging in strategic acquisitions. In April 2023, Difgen Pharmaceuticals acquired Aveva Drug Delivery Services to enhance its drug delivery capabilities and integrate advanced technologies.

• Advanced Technologies: This acquisition highlights the strategic importance of integrating advanced drug delivery systems like transdermal delivery systems (TDS) and oral dissolvable films (ODF) to meet evolving market needs.

Market Segmentation

The transmucosal drug delivery devices market is segmented by:

• Type: Passive and active transdermal drug delivery.
• Drug Type: Including buccal tablets, oral sprays, sublingual films, wafers, gels, medicated confectionery, and other drug types.
• Indication: Pain management, addiction treatment, hormonal therapies, and other indications.
• End User: Academic and research institutes, pharmaceutical and biotechnology companies, diagnostic laboratories, and hospitals.

Regional Insights

In 2023, North America emerged as the largest region in the transmucosal drug delivery devices market. The region’s growth is primarily driven by advanced healthcare infrastructure, high adoption rates of new technologies, and significant investment in research and development.

Request A Sample Of The Global Transmucosal Drug Delivery Devices Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=16812&type=smp